As the CEO and founder of Merakris Therapeutics, I was extremely proud to partner with Keeler to help advance our missions. Their forward-thinking culture aligned perfectly with our values, and they have proven to be an ideal partner for our Opticyte Amniotic Ocular MatrixRM product line. This state-of-the-art biological barrier graft protects damaged eye surfaces during healing in patients who may suffer from corneal defects, such as dry eye disease.